HeatCheck aims to develop a scalable, commercial-grade, open-source, AI-driven toolchain that merges meter data with ubiquitous wireless heat cost allocator data to optimize heating systems in apartment buildings. District heating operators have focused on supply temperatures and flows to satisfy various demand profiles. However, they typically overlook end-users and substations as beyond their control. Thus, buildings are bottlenecks in the transition to low-temperature district heating. The HeatCheck toolchain empowers building owners to operate apartment buildings with unprecedented efficiency, in turn, paving the path for low-risk, near-term investments in renewable energy sources and large-scale investments in heat pumps in district heating networks. Ista and Techem controls roughly two-thirds of the Danish market for allocating heat costs in apartments, and combined provide heat metering in 25 million apartments globally. HeatCheck seeks to leverage that massive data to detect and diagnose faulty heating systems automatically, optimize central controls to constrain heat losses and minimize harm from misuse, improve service offerings using digital-twin-based analytics and actively shift peak loads. The HeatCheck project provides a unique opportunity for heat cost allocation companies, district heating companies, building operators and research institutions to develop new services generating novel revenue streams and ensuring a cost-effective green transition.

Each year, more than one million planned surgeries in EU and US result in blood transfusion, reoperation or fatality due to uncontrolled bleeding in the hospital. No single dressing can effectively control severe arterial or venous bleedings. This project will develop a new class of general hemostatic dressings for surgical applications in hospitals for controlling bleedings. It will be the first treatment of bleeding, which uses Tissue Factor (TF), the endogenous initiator and accelerator of the extrinsic coagulation path responsible for hemostasis. Previously, we have demonstrated that the binding of recombinant extracellular TF permanently to a dressing using a chemical linker efficiently stops severe carotid artery bleedings in minipigs, outperforming competing systems. Also, we have shown that the active TF protein in our system is permanently bound, is stable over time and safe. In this project, we will develop a novel manufacturing technology, which can convert any general dressing system used in planned surgery – gauze, swaps, sponges, etc. - to become highly hemostatic in one simple high-yield manufacturing processing step. The new hemostatic dressing systems will be tested in a pre-clinical laparoscopic ovary and in a spleen bleeding model, to illustrate the utility of the technology in some of the most challenging surgical applications.